Pacific Edge (Pacific Edge) ROCE % : -52.38% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Pacific Edge ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pacific Edge's annualized ROCE % for the quarter that ended in Mar. 2024 was -52.38%.

Pacific Edge ROCE % Historical Data

The historical data trend for Pacific Edge's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacific Edge ROCE % Chart

Pacific Edge Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

-128.78

-85.29

-32.82

-32.66

-49.03

Pacific Edge Semi-Annual Data
	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
ROCE %	Get a 7-Day Free Trial															-23.89	-27.73	-42.22	-49.13	-52.38

Pacific Edge ROCE % Calculation

Pacific Edge's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	-22.042	/	( ( (60.285 - 5.132)	+	(39.81 - 5.059) )	/ 2 )
	=	-22.042	/	( (55.153	+	34.751)	/ 2 )
	=	-22.042	/	44.952
	=	-49.03 %

Pacific Edge's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Sep. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Sep. 2023 )		(Q: Mar. 2024 )
	=	-19.85	/	( ( (45.228 - 4.192)	+	(39.81 - 5.059) )	/ 2 )
	=	-19.85	/	( ( 41.036	+	34.751 )	/ 2 )
	=	-19.85	/	37.8935
	=	-52.38 %

(1) Note: The EBIT data used here is two times the semi-annual (Mar. 2024) EBIT data.

Pacific Edge (OTCPK:PFGTF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pacific Edge ROCE % Related Terms

Thank you for viewing the detailed overview of Pacific Edge's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pacific Edge (Pacific Edge) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Pacific Edge Ltd (OTCPK:PFGTF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

PEB:New Zealand PEB:Australia

Address

87 St David Street, P.O. Box 56, Dunedin, STL, NZL, 9016

Website

https://www.pacificedgedx.com

Pacific Edge Ltd is a NewZealand based company involved in developing and commercializing diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. The company operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses world wide; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, New Zealand, and the Rest of the World.